TNF inhibitor

No Recurrent Cancer Risk With Biologic Treatment of RA

Save

Patients with rheumatoid arthritis (RA) who had a history of cancer did not have an increased risk of new or recurrent cancers if treated with biologic therapies, a meta-analysis found.

Guselkumab Treats Axial Disease in Psoriatic Arthritis

Save

Pooled analysis of the DISCOVER-1 and DISCOVER-2 trials have shown that guselkumab, an IL-23 inhibitor, was effective and safe in psoriatic arthritis (PsA) patients with axial involvement and imaging-confirmed sacroiliitis.

Different Regimens but Equal Outcomes in Polyarticular JIA

Save

CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen.

This prospective observational study used data from the STOP-JIA trial (Start Time Optimization of

High Drug Switching and Low Persistence in Rheumatoid Arthritis

Save

Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians.

This retrospective analysis assessed treatment patterns among patients newly initiated on biologic

Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors

Save

Dr. Jack Cush is joined by Drs. Roy Fleischmann (Dallas), Allan Gibofsky (NYC), and Artie Kavanaugh (San Diego) to discuss the 9/2/21 FDA Drug Safety Communication regarding the cardiovascular and cancer risks arising from the Pfizer 1133 (ORAL Surveillance) tofacitinib study, but also applied

TNF Inhibitor Induced IgA Vasculitis in IBD

Save

A new descriptive series shows an uncommon association between IgA vasculitis (IgAV) and inflammatory bowel diseases (IBD), with most cases interestingly arising after  or during anti-TNF-α therapy.

A retrospectively analysis of the GETAID and FVSG networks identified, 43 patients

Drug Choices After First TNF Inhibitor in RA

Save

TNFi are frequently used first line in RA patients; and a new analysis shows that repeat use of TNFi dominates over the use of non-TNFi biologics when the initial TNFi therapy has failed. This retrospective analysis of commercial insurance records analyzed the patterns of drug use in adult RA

RheumNow Podcast – COVID Marching Amidst the Madness (8.27.2021)

Save

We have a lot of news, information and approvals to review and discuss, though I need to begin with what's weighing heavily on my mind. After, we'll dive into what we learned this week.

ACR Guidance on Timing of 3rd Dose Booster with Immunomodulatory Drugs

Save

The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases following recent recommendations from the CDC that certain immunocompromised patients receive a third dose of an available mRNA

Biologic Therapy of Psoriasis May Prevent Psoriatic Arthritis

Save

Another retrospective cohort study has shown that biologic treatment of psoriasis may reduce the subsequent incidence of psoriatic arthritis (PsA).

Analysis of electronic medical records of a large HMO identfied psoriasis patients who had received treatment for psoriasis (but were

EULAR Points on Managing Difficult Rheumatoid Arthritis

Save

A EULAR task force has promulgated several points to consider in managing difficult-to-treat RA. These "points" are unique in directing the rheumatologist's attention to the potential for misdiagnosis and the impact of comorbid conditions on what is perceived as poorly controlled RA.

Biologics Reduce Surgical Needs in RA

Save

In Canada, biologic DMARDs (bDMARDs) were introduced after 2001, and since that time there have been significant reductions in hip and knee arthroplasty (THA/TKA) among patients with rheumatoid arthritis (RA), but not in patients with osteoarthritis (OA).

A cohort of RA and OA

RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)

Save

It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy and safety; and an interesting case plus a question from one of our readers submitted via Back Talk. This and more in this week's podcast. Let's dive in.

Rheumatoid Arthritis Offspring Show Normal School Performance

Save

A prospective, longitudinal study of the cognitive development of children born to mothers with rheumatoid arthritis (RA) demonstrates normal development as measured by comparative school test scores.

This study included Danish children born 1995–2008 (n=934) and compared to non-RA

Shingles Risk with JAK Inhibitors and Other Biologics

Save

Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.

RA patients from the German RABBIT register were prospectively enrolled (2007 - 2020)

No Cancer Risk with TNF Inhibitors in Rheumatoid Arthritis

Save

The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs).

Cardiovascular Prevention Lacking in Rheumatoid Arthritis

Save

An increased cardiovascular disease (CVD) risk in rheumatoid arthritis is well known and feared but an RA cohort study suggests that preventive medication use in RA patients lags behind that seen in diabetes mellitus (DM).

DMARD Effects on COVID-19 Outcomes

Save

Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (